No radical developments? Near all medical expense is at present due to age-related disease. When the distinct and understood causes of aging can be treated as medical conditions, which at present they are not, then that expense will be reduced. Rejuvenation biotechnology to repair the causes of aging is a going concern. The first legitimate, actual, real rejuvenation therapies that turn back one of the root causes of aging are in early human trials and preclinical development. They are largely low-cost. Efforts to slow aging by slowing those causes are a larger going concern. Those approaches are similarly largely low-cost. It is clearly the case that a tipping point has been reached in support for efforts to treat aging in order to, eventually, indefinitely postpone the mortality, cost, and suffering of old age.

Just ahead, in the next few years, there is the start of a massive shift in medicine for the old, medicine associated with the greatest costs. It is beginning now.